搜尋結果
2022年11月7日 · November 7, 2022. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal ® (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) in ...
2024年3月29日 · March 29, 2024. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant Myonal ® (generic name: eperisone hydrochloride) in ...
其他人也問了
Who makes merislon 6 mg tablet?
What is the right dosage of merislon?
What is merislon used for?
How to take merislon?
2021年6月30日 · DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
2021年3月2日 · For Print March 2, 2021 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO ® (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or ...
TOKYO AND NEW YORK, June 18, 2021 -- Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
- For overseas: Lenvima, Fycompa, Zonegran®, Merislon®, Glakay® etc. Panoramic views of Kawashima Industrial Park Main facilities: (1) The 5th manufacturing building (2) Pilot Plant (3) The 4th manufacturing building (4) The 3rd manufacturing building ①①
